UBS Group
FTH

UBS Group’s Faeth Therapeutics FTH Stock Holding History

UBS Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Buy
21,541
+17,012
+376% +$393K ﹤0.01% 6186
2026
Q1 		$143K Buy
+4,529
New +$90.5K ﹤0.01% 6814
2025
Q4 		– Sell
-873
Closed -$8.25K – 11105
2025
Q3 		$8.25K Sell
873
-1,267
-59% -$10.5K ﹤0.01% 8673
2025
Q2 		$18.4K Buy
2,140
+13
+0.6% +$93 ﹤0.01% 8500
2025
Q1 		$16.8K Buy
+2,127
New +$20.2K ﹤0.01% 8344
2024
Q4 		– Hold
0
– – – 9863
2024
Q2 		– Sell
-7
Closed -$146 – 10039
2024
Q1 		$146 Buy
+7
New +$121 ﹤0.01% 8781
2023
Q3 		– Sell
-326
Closed -$7.42K – 9929
2023
Q2 		$7.42K Buy
326
+154
+90% +$4.51K ﹤0.01% 7294
2023
Q1 		$5.16K Buy
172
+117
+213% +$3.47K ﹤0.01% 8077
2022
Q4 		$1.64K Sell
55
-601
-92% -$17.7K ﹤0.01% 9826
2022
Q3 		$20K Sell
656
-17
-3% -$668 ﹤0.01% 7407
2022
Q2 		$31K Sell
673
-8
-1% -$300 ﹤0.01% 6366
2022
Q1 		$31K Sell
681
-439
-39% -$34.9K ﹤0.01% 6967
2021
Q4 		$130K Buy
1,120
+1,070
+2,140% +$160K ﹤0.01% 6054
2021
Q3 		$11K Buy
50
+15
+43% +$2.73K ﹤0.01% 7905
2021
Q2 		$7K Sell
35
-70
-67% -$17.3K ﹤0.01% 8351
2021
Q1 		$31K Buy
+105
New +$35.1K ﹤0.01% 6990

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

UBS Group's FTH Position: Q2 2026 in Review

UBS Group increased its Faeth Therapeutics (FTH) stake by 376% in Q2 2026, buying an estimated $393K and bringing the position to 21,541 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #6186.

UBS Group first reported a position in FTH in Q1 2021 and has held it in 16 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • UBS Group held 21,541 shares of Faeth Therapeutics worth $539K as of Q2 2026.
  • UBS Group bought 17,012 Faeth Therapeutics shares in Q2 2026, an estimated $393K.
  • Faeth Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6186 holding.
  • UBS Group first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.